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STEM CELLS AND REGENERATION RESEARCH ARTICLE
MicroRNA deep sequencing in two adult stem cell populations
identifies miR-501 as a novel regulator of myosin heavy chain
during muscle regeneration
Amir Mizbani1,2, Edlira Luca1, Elisabeth J. Rushing3 and Jan Krützfeldt1,2,4,*
ABSTRACT
MicroRNAs (miRNAs) are important regulators of skeletal muscle
regeneration, but the underlying mechanisms are still incompletely
understood. Here, comparative miRNA sequencing analysis of
myogenic progenitor cells (MPs) and non-myogenic fibroblast-
adipocyte progenitors (FAPs) during cardiotoxin (CTX)-induced
muscle injury uncovered miR-501 as a novel muscle-specific
miRNA. miR-501 is an intronic miRNA and its expression levels in
MPs correlated with its host gene, chloride channel, voltage-sensitive
5 (Clcn5). Pharmacological inhibition of miR-501 dramatically blunted
the induction of embryonic myosin heavy chain (MYH3) and, to a
lesser extent, adult myosin isoforms during muscle regeneration, and
promoted small-diameter neofibers. An unbiased target identification
approach in primarymyoblasts validated gigaxonin as a target of miR-
501 that mimicked the effect of miR-501 inhibition on MYH3
expression. In the mdx mouse model, which models a pathological
disease state, not only was miR-501 induced in regenerating skeletal
muscle, but also its serum levels were increased, which correlated
with the disease state of the animals. Our results suggest that miR-
501 plays a key role in adult muscle regeneration andmight serve as a
novel serum biomarker for the activation of adult muscle stem cells.
KEY WORDS: MicroRNA, Skeletal muscle, Regeneration, Myosin,
Serum
INTRODUCTION
Skeletal muscle function is crucial for the maintenance of health. It
has been estimated that about 80% of cancer patients experience
muscle wasting, and that the loss of muscle mass contributes
significantly to decreased quality of life or even death (Cohen et al.,
2015). Loss of muscle mass can be caused by factors intrinsic to
adult myofibers such as degradation of myofibrillar proteins by the
ubiquitin-proteasome pathway (Cohen et al., 2009, 2012). However,
muscle mass is also determined by the capacity of skeletal muscle
to regenerate. Regeneration of skeletal muscle depends on the
activation of myogenic progenitors (MPs), and their proliferation
and differentiation into committed myoblasts, which finally fuse to
build or repair myofibers. Activation of inflammatory pathways in
MPs has been shown to contribute to muscle wasting in cachexia
(He et al., 2013). Transplantation of MPs in aged mice was able to
prevent muscle loss (Hall et al., 2010) and improving the regenerative
capacity of MPs during aging improved muscle strength (Cosgrove
et al., 2014). Skeletal muscle regeneration resembles the myogenesis
process during development in many aspects, such as the expression
of developmental myosins. The embryonic isoform of myosin,
MYH3, is expressed during the early phase of regeneration and is
slowly replaced in the course of the following 2-3 weeks by the adult
myosin heavy chain (MHC) isoforms (Schiaffino et al., 2015). This
renders developmental myosin a marker for skeletal muscle
regeneration in both animal models and human myopathies
including rhabdomyosarcoma (Schiaffino et al., 1986). The switch
from embryonic myosin to type II fast adult MHCs is nerve
independent, whereas the switch to type I MHCs is predominantly
driven by nerve activity (d’Albis et al., 1988). The regulation of the
initial expression of developmental and adult myosins during muscle
regeneration is only poorly understood.
MicroRNAs (miRNAs) are a class of short non-coding RNAs of
20-24 nucleotides in length. Several miRNAs specific to striated
muscle, also referred to as myomiRs, have been described to date,
such as miR-1, -133a/b, -206, -208a/b and -499 (Chen et al., 2009),
and have been shown to regulate myogenesis. Most myomiRs are
expressed in both cardiac and skeletal muscle, although miR-208a
and miR-206/miR-133b are specific to cardiac and skeletal muscle,
respectively (Chen et al., 2009). miR-1 and miR-206 partake in
promoting differentiation over proliferation of stem cells. miR-1
targets histone deacetylase 4, which is a repressor of muscle
differentiation (Chen et al., 2006), whereas miR-1 and miR-206
repress paired box 7, an essential factor for the muscle
differentiation process (Chen et al., 2010). miR-206 is also
involved in terminal differentiation of myoblasts by targeting
connexin-43 (also known as gap junction protein, alpha 1)
(Anderson et al., 2006) and in the inhibition of cell proliferation
by targeting the p180 subunit of DNA polymerase-α (Kim et al.,
2006). Despite the absence of an overt skeletal muscle phenotype,
miR-206 knockout mice show a remarkably delayed regenerative
response to cardiotoxin (CTX)-induced muscle injury (Liu et al.,
2012). When crossed to the muscle dystrophy mouse model mdx, it
was observed that lack of miR-206 aggravates the dystrophic
phenotype (Liu et al., 2012). In contrast to miR-1 and miR-206,
miR-133 inhibits the differentiation of myoblasts and promotes their
proliferation by repressing serum response factor (Chen et al.,
2006). Interestingly, the miR-208 family, including miR-208a/b and
miR-499, are all intronic miRNAs located and co-transcribed with
various myosin genes. miR-208a is encoded within the Myh6 geneReceived 31 January 2016; Accepted 22 September 2016
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(α-myosin heavy chain) and is expressed specifically in cardiac
muscle (van Rooij et al., 2007), whereas miR-208b andmiR-499 are
processed from introns inMyh7 (β-myosin heavy chain) andMyh7b
(myosin heavy chain 7b) genes, respectively (Chen et al., 2009).
Functioning in a redundant manner owing to identical seed
sequences, the last two miRNAs control the fiber type switch in
skeletal muscle by targeting Sox6, Sp3, Purb and HP-1b
(haptoglobin) (van Rooij et al., 2009). Mice lacking both miR-
208b and miR-499 have substantially fewer type I fibers in soleus
muscle, whereas overexpression of miR-499 in soleus leads to the
switch of fast type II myofibers to slow type I myofibers (van Rooij
et al., 2009). Whether a muscle-specific miRNA regulates myosin
formation in regenerating skeletal muscle is still unknown.
Here, we report a novel muscle-specific miRNA, miR-501, located
in an intron of isoform-2 of theClcn5 gene and expressed specifically
in activated MPs and newly formed myofibers. miR-501 induction in
activated muscle stem cells parallels the progression of muscle
regeneration processes and regulates the expression ofMHC in newly
formed fibers. Furthermore, surges in miR-501 levels in serum of
mdx mice correlate with the regenerative phases in muscle. Overall,
we propose miR-501 as a new myomiR and biomarker of MP
activation that regulates the transition of embryonic myosin heavy
chain to adult isoforms during skeletal muscle regeneration.
RESULTS
microRNA deep sequencing in two adult stem cell
populations
To identify a novel muscle-specific miRNA, we analyzed miRNA
expression in activated MPs compared with a non-myogenic cell
population, fibrocyte-adipocyte progenitors (FAPs). Activation of
MPs was achieved by a single intramuscular CTX injection. Previous
studies have indicated that the proliferation response is maximal
3 days after CTX injection (Joe et al., 2010). Indeed, we observed that
a single pulse of 5-ethynyl-2′-deoxyuridine (EdU) labeled ∼60% of
MPs and∼30% of FAP cells (Fig. 1A,B). As expected, MPs or FAPs
from uninjected muscle showed only minor proliferation activity
(Fig. 1B). To identify the miRNAs specifically expressed in MPs, we
collected MPs and FAPs using fluorescence-activated cell sorting
(FACS) for alpha7-integrin+SCA1−lin− cells or alpha7-
integrin−SCA1+lin− cells, respectively, 3 days after CTX
application and isolated RNA for Illumina deep sequencing of
miRNAs.Overall, we detected 478 and 535miRNA sequences in two
independent biological replicates of activated MPs. Five miRNAs
were highly expressed representing at least 1%of all retrievedmiRNA
sequences and were at least fivefold enriched in MPs versus FAPs
(Fig. 1C; Table 1). Importantly, all five miRNAs were conserved
between mice and humans (mirbase.org). Next, we compared the
expression of these miRNAs as well as miR-1 between quiescent and
activated MPs and FAPs and adult skeletal muscle using qRT-PCR
(Fig. 2A). Consistent with our sequencing data, miR-1 was expressed
at a low level in MPs and FAPs compared with adult skeletal muscle,
and the five selectedmiRNAs had higher expression in activatedMPs
compared with activated FAPs. However, only miR-501 had
substantially higher expression in activated versus quiescent MPs as
well as in activatedMPs compared with normal adult skeletal muscle.
These results indicated that miR-501 in skeletal muscle is induced
specifically in activated MPs during muscle regeneration.
Expression ofmiR-501 and its host gene isoform-2 of Clcn5 in
regenerating skeletal muscle
To improve our understanding of the regulation of miR-501 during
muscle regeneration, we analyzed the kinetics of miR-501 at
different time points after CTX-induced muscle injury. We also
analyzed expression of miR-1, which is known to be a marker of
adult non-regenerative muscle, and miR-206, which is induced
Table 1 . Relative abundance of the five miRNAs selected based on
absolute expression level and enrichment in activated MPs (acMPs)
compared with activated FAPs (acFAPs)
MicroRNA acMP RPM (×103) acFAP RPM (×103) Ratio
miR-27b-3p 85.4 12.4 6.9
miR-486-5p 45.7 1.6 28.6
miR-501-3p 44.3 3.5 12.6
miR-10a-5p 22.5 0.5 45.0
miR-146a 22.1 1.6 13.8
RPM, reads per million.
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Fig. 1. miR-501 is highly enriched in activated myogenic progenitors. TA
muscles were injected with CTX and analyzed 3 days later. (A) MPs and FAPs
were identified based on their distinct expression pattern of SCA1 and alpha
7-integrin. Orange: PE+ gate; green: APC+ gate. (B) Mice were injected
intraperitoneally with 10 µg EdU per gram body weight 12 h before harvesting.
Proliferation was measured by EdU incorporation assay using FACS. Shown
are cell counts based on Alexa Fluor 647 (AF647) staining. (C) Results of small
RNA deep sequencing, comparing activated MPs and FAPs, n=2, each
sample representing a pool of cells obtained from seven to nine mice for MPs
and two mice for FAPs. The five miRNAs that were identified as being highly
expressed and at least fivefold enriched in MPs versus FAPs are marked.
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during muscle differentiation (Liu et al., 2012). As expected, miR-1
was expressed at a low level during regeneration whereas miR-206
expression was strongly induced 6 days after CTX injection
(Fig. 2B). Expression levels of miR-206, however, remained
unchanged during the first 3 days of muscle regeneration when
MP proliferation is maximally stimulated. By contrast, miR-501
expression was immediately upregulated after muscle injury,
providing a more accurate representation of the progression of
muscle regeneration (Fig. 2B). We then determined the expression
of miR-501 by qRT-PCR in various mouse tissues and identified
regenerating skeletal muscle as the tissue with the highest
expression of this miRNA (Fig. 2C). Northern blotting confirmed
expression of miR-501 in regenerating muscle as well as in primary
myoblasts and myotubes (Fig. 2D). Importantly, miR-501 was not
detected in non-regenerating muscle, adult kidney or brain
(Fig. 2D). No major regulation was observed for miR-501 during
differentiation of myoblasts in contrast to miR-1 (Fig. 2D-F).
Together, these data identify miR-501 as a myomiR specific to adult
miR-10a
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0.0
0.5
1.0
1.5
* ***
*
miR-27b
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0.0
0.5
1.0
1.5
*
miR-146a
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0.0
0.5
1.0
1.5
2.0
*
***
miR-486
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0
1
2
3
4
miR-501
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0
2
4
6
***
**
miR-1
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
qu
MP
ac
MP
qu
FA
P
ac
FA
P SM
SM
+C
TX
0.0
0.5
1.0
1.5
***
A
Days after CTX injection
Re
la
tiv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
0 3 6 9
0
5
10
15
20
miR-206
miR-1
miR-501
B
miR-501
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
Br
ain
Lu
ng
St
om
ac
h
Ki
dn
ey
Sm
. in
t.
Sp
lee
n
WA
T
Co
lon
He
art
Liv
er
TA
 m
us
cle
TA
- D
3 C
TX
0
1
2
3
4
5
C
miR-501
tRNA
D
Primary myoblasts
Days of differentiation
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
0 1 2 3 4 5
0
5
10
15
20
miR-1
miR-206
miR-501
E
Primary myoblasts
Days of differentiation
R
el
at
iv
e 
ex
pr
es
si
on
 le
ve
l
(A
.U
.)
0 1 2 3 4 5
0
1
2
3
4
Tnni
Myh3
Myogenin
MyoD
Pax7
F
Fig. 2. miR-501 expression is specific to myogenic progenitors and induced during skeletal muscle regeneration. (A) Expression of the selected miRNAs
in MPs and FAPs sorted from normal (SM) or CTX-injected (SM+CTX) TA skeletal muscle, measured by qRT-PCR. miR-1 was measured as an adult-muscle-
specific miRNA. n=4-6. acFAP, activated FAPs; acMP, activated MPs; quFAP, quiescent FAPs; quMP, quiescent MPs. (B) Expression of miR-501, miR-206
and miR-1 up to 9 days after CTX injection, measured as in A. n=3 for each time point. (C) Expression of miR-501 in different mouse tissues measured by qRT-
PCR. n=5 for TA-CTX, n=3 for the other tissues. D3 CTX, day 3 after CTX treatment; Sm. Int., small intestine; WAT, white adipose tissue. (D) Confirmation
of tissue-specific miR-501 expression in CTX-injected TA, primary myoblasts, and myotubes by northern blotting. Ethidium bromide staining of tRNA is shown as
loading control. (E,F) The indicated muscle-specific miRNAs (E) or muscle differentiation markers (F) were measured during differentiation of mouse primary
myoblasts after serumwithdrawal for the indicated time points. n=3. Datawere normalized to sno234 in A,B,C and E, and to 18S RNA in F and presented asmean
±s.e.m. relative to normal TA muscle or undifferentiated myoblasts. *P<0.05, **P<0.01, ***P<0.001, Student’s t-test. CTX, cardiotoxin; SM, skeletal muscle.
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muscle stem cells and one which is induced specifically during the
activation of these cells in the process of regeneration.
To address the mechanisms that drive the expression of miR-
501 in muscle precursor cells, we looked into the genomic
residence of this miRNA. Intriguingly, miR-501 is located in an
intron of the chloride channel 5 gene (Clcn5) in a cluster with
other miRNAs (Fig. 3A). An alternative splicing upstream of exon
5 leads to the generation of two splice variants of Clcn5 in both
mouse and humans (NCBI RefSeq). In mouse, splice variant 1
(NM_016691) encodes a 746-amino acid protein with a start site at
exon 4, whereas splice variant 2 (NM_001243762) includes exons
1, 2 and 3, hence encoding a protein with 70 additional amino
acids at its N terminus. Interestingly, the intron harboring the
miRNA cluster is located between exons 2 and 3 in mouse and 3
and 4 in human, which are present only in isoform-2 of Clcn5.
Alignment of mouse and human miR-501-3p sequences indicate a
high degree of conservation (Fig. 3B). We returned to our RNA
deep sequencing data to analyze the expression of the other
intronic miRNAs in MPs. However, we observed that only miR-
501 and its closest neighbor miRNA, miR-362, were detectable
(Fig. 3C). Possibly, post-transcriptional mechanisms might dictate
the preferential expression of miR-501 compared with the other
intronic miRNAs.
Isoform-1 of the Clcn5 gene encodes a Cl−/H+-exchanger highly
expressed in kidney, where it plays a crucial role in the process of
endocytosis in the proximal tubule (Piwon et al., 2000; Christensen
et al., 2003). We analyzed the expression of both Clcn5 isoforms
during skeletal muscle regeneration. Intriguingly, we observed that
isoform-2, but not isoform-1, is highly induced (Fig. 4A). Whereas
we could confirm that isoform-1 expression is highest in kidney
(Fig. 4B,C), we observed that isoform-2 expression is specific to
muscle precursor cells (Fig. 4D). Furthermore, in progenitor cells
isolated from adult skeletal muscle,Clcn5 isoform-2 is the dominant
isoform with comparable expression levels in activated and
quiescent MPs (Fig. 4E,F). This expression pattern indicates a
common promoter element shared by Clcn5 isoform-2 and miR-
501. However, the strong induction of miR-501 upon activation of
MPs is not observed for Clcn5 isoform-2 and indicates additional
regulatory steps at the post-transcriptional level of the miR-501
precursor.
Silencing of miR-501 in vivo prevents myosin heavy chain
expression during muscle regeneration
Our next aim was to determine the function of miR-501 during the
process of muscle regeneration. For the inhibition of miR-501
in vivo, we injected antagomirs against miR-501, scrambled control
antagomirs or PBS intramuscularly. Injection of antagomir-501
markedly reduced miR-501 levels in both MPs and regenerating
muscle (Fig. 5A). Using EdU incorporation assays and flow
cytometry analysis, we did not observe any change in proliferation
rate of MPs 4 days after the induction of muscle injury (data not
shown). Interestingly, muscle protein lysates separated by SDS-
PAGE and stained with Coomassie Blue revealed a remarkable and
specific decrease in dye intensity at the high molecular weight range
A
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(Fig. 5B), suggesting alteration of MHC levels. Indeed, western blot
analysis for MYH3, the first type of MHC expressed in newly built
fibers, revealed a dramatic decrease of this protein when miR-501
was inhibited (Fig. 5C). As muscle regeneration proceeds, MYH3 is
replaced by other adult MHC isoforms. Western blot analysis of
regenerating muscles at later time points also showed lower
abundance of adult MHCs as measured with an antibody
detecting all MHC isoforms after miR-501 was inhibited
(Fig. 5C). Fifteen days after muscle regeneration was induced this
difference was no longer present (Fig. 5C), and there was also no
difference in muscle weight (data not shown). At the gene
expression level, inhibiting miR-501 significantly blunts the
induction of the Myh3 transcript on day 4 of regeneration, but on
day 6, Myh3 expression in both control and antagomir-treated
muscles returns to baseline (Fig. 5D). This indicates that the strong
inhibition of MHY3 protein at day 6 occurs independently of
transcription. In addition, we observed an upregulation of the adult
muscle markers myoglobin and myostatin, suggesting that
downregulation of MHC might not be a consequence of delayed
differentiation. Immunofluorescence analysis of fiber size in the
regenerating muscles demonstrated a significant shift towards
smaller fibers after miR-501 inhibition (Fig. 5E,F). We conclude
that miR-501 is crucial for MHC expression in newly formed
myofibers mainly at the post-transcriptional level, hence its absence
leads to a decrease in fiber size.
Identification of miR-501 target genes
In order to identify the relevant targets of miR-501, we performed
quantitative analysis of the transcriptome in myoblasts with and
without inhibition of miR-501. mRNA sequencing was performed
on RNA isolated from primary myoblasts transfected with either
control antagomir or antagomir-501. We aligned the list of all
detected transcripts with the list of predicted miR-501 targets in
mouse and human, generated by TargetScan v6.2. Among the
overlapping genes, those which were significantly upregulated
(P<0.05) and were highly conserved among mammals were
considered for further analysis (Fig. 6A; Fig. S1A,B).
Importantly, we could confirm six of the selected genes as
potential miR-501 targets as their expression decreased or
increased after transfection of primary myoblasts with miR-501
mimics or antagomirs, respectively (Fig. 6B). In order to validate
these genes as miR-501 targets, we cloned the part of their 3′UTRs
that harbored the predicted miR-501-binding site in luciferase
reporter vectors. Analysis of luciferase activity after co-transfection
with a miR-501mimic confirmed that all selected genes have at least
one responsive miR-501 binding site (Fig. S1C). To investigate
whether these genes underlie the effect of miR-501 on MYH3
expression in newly formed myofibers, we cloned the protein-
coding sequence of the validated target genes into expression
vectors. Overexpression in primary myoblasts was confirmed at the
transcriptional level for all constructs (data not shown). For each
construct, we then analyzed MYH3 protein levels 2 days after
induction of differentiation. Overexpression of only one of the target
genes, Gan, was able to reduce MYH3 levels in primary myoblasts
(Fig. 6C), thereby mimicking the in vivo effect of inhibiting miR-
501 in skeletal muscle. The downregulation of MYH3 after
overexpression of Gan was rescued by the proteasome inhibitor
MG-132 (Fig. 6D). These results are in line with reports of
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gigaxonin (also known as giant axonal neuropathy) being an E3
ligase substrate adaptor that targets proteins for proteasomal
degradation and our findings that MYH3 is inhibited post-
transcriptionally in the absence of miR-501. Luciferase assays
using the 3′UTR of Gan harboring a mutated miR-501-binding site
confirmed Gan as a direct miR-501 target (Fig. 6E). Inhibition of
miR-501 using antagomirs increased Gan mRNA in regenerating
muscle at day 4 after CTX, but not in MPs (Fig. 6F). Together, our
results indicate that miR-501 is upregulated during muscle
regeneration in myogenic progenitors and newly formed fibers
where it regulates developmental myosins by its target gene Gan.
miR-501 indicates muscle regeneration in themdxmouse
Our results so far identified a novelmuscle-specificmiRNA in amodel
of injury-induced muscle regeneration. We next addressed whether
miR-501 is also upregulated inmuscle from a geneticmodel ofmuscle
regeneration, themdxmouse. miR-501 expression was more than five
times higher in tibialis anterior (TA) muscles from mdx mice than in
those from age-matched wild-type C57BL/6 controls (Fig. 7A). As
previously reported (Roberts et al., 2012), miR-206 levels were
induced, whereas miR-1 and miR-133 were unchanged or
downregulated in mdx mice compared with control (Fig. 7A). Next,
we analyzed whether miR-501 was present in the serum of mdx mice
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and whether it correlated with the regeneration status of muscle,
similar to previously reported myomiRs (Roberts et al., 2012).
Comparison of miR-501 levels in serum from age-matched mdx and
C57BL/6 mice showed significantly higher abundance of this miRNA
and also miR-206, miR-1 and miR-133, inmdxmice (Fig. 7B). Time-
course experiments revealed that the levels of all myomiRs including
miR-501 correlated with serum creatine kinase activity (Fig. 7C-G).
SerummiRNAs levels peak between 8 and 10 weeks of age, which is
in line with the high proliferation/regeneration reported for the mdx
mouse during this period (McGeachie et al., 1993; Turk et al., 2005;
Zhou et al., 2006). Together, these results strengthen the view of miR-
501 as a miRNA specific to muscle regeneration.
We therefore propose that miR-501 expression in muscle
precursor cells is mediated by its host gene Clcn5 isoform-2.
During muscle regeneration, activation of MPs leads to post-
transcriptional regulation and a surge in miR-501 expression in
neofibers that supports myosin expression by targeting genes such
as gigaxonin (Fig. 7H).
DISCUSSION
Our study identifies a novel muscle-specific miRNA that regulates
myosin during neofiber formation. miR-501 was only detectable in
regenerating skeletal muscle and muscle progenitor cells, and loss-
of-function studies using pharmacological inhibitors in vivo
demonstrated a profound loss of MYH3 protein and to a lesser
degree adult MHC after muscle injury was induced. Strikingly, an
unbiased target identification approach in primary muscle cells
validated gigaxonin as a target of miR-501, overexpression of which
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in differentiating muscle cells in vitro mimicked the effect of
antagonizing miR-501 on myosin levels observed in vivo.
Gigaxonin is a ubiquitously expressed protein (Bomont et al.,
2000) that acts as an E3 ligase adaptor and targets proteins for
degradation by the proteaseome (Mahammad et al., 2013) in
different cell types such as dermal fibroblasts (Sabatelli et al., 1992)
and neurons (Ben Hamida et al., 1990). Mutations in the gene Gan,
which encodes gigaxonin, can cause an autosomal recessive
sensorimotor disease, called giant axonal neuropathy (Bomont
et al., 2000), but a specific function for skeletal muscle has not been
reported yet. Interestingly, in non-muscle tissues, gigaxonin targets
intermediate filaments, such as vimentin (Sabatelli et al., 1992) or
keratin (Treiber-Held et al., 1994) for proteasomal degradation,
whereas in myofibers, we observed that gigaxonin did not affect the
intermediate filament desmin, but instead the larger myosin.
The myosin composition of adult muscle changes depending on
the physiological demands, especially during regeneration when
MYH3 appears first and is later replaced by the adult isoforms. The
effects of miR-501 inhibition were strongest on the newly formed
myofibers and decreased as regeneration progressed and adult
myofibrils were formed. These kinetics support the notion that miR-
501 action involves inhibition of the proteasome. Several studies
have shown that mature myofibrils are not degraded by the activated
proteasome (Solomon and Goldberg, 1996) and additional enzymes
are required to allow for the solubilization of ubiquitylated
myofibrillar structures (Piccirillo and Goldberg, 2012). Therefore,
during the early stages of regeneration, miR-501 might provide
protection from the proteasome for the newly synthesized MYH3
protein as well as the MHC adult isoforms that are not incorporated
yet into myofibrils. As myofibers mature and myofibrils form and
stabilize, they are no longer targets for the proteasome and miR-501
is no longer required and is therefore downregulated. Interestingly,
although the proteasome is responsible for the degradation of
80-90% of the muscle proteins in vivo (Goll et al., 2008), it is much
less abundant in myotubes where proteolysis depends primarily on
autophagy (Zhao et al., 2007). Indeed, inhibition or overexpression
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of miR-501 in primary muscle cells in vitro did not affect MYH3
levels (data not shown). The specific loss of a high molecular weight
band that we observed in our SDS-PAGE analysis from muscle
samples provides evidence against the involvement of the calpain
system in the miR-501 pathway (Sugita et al., 1980).
The role of the transition of developmental myosins in muscle
fiber regeneration is poorly understood. Our study indicates that it
affects neofiber diameter although the effect size was subtle. It is
possible that repeated CTX injections are required for more
profound effects or that myosin transition has a stronger impact
after a more physiological regeneration stimulus, e.g. after eccentric
exercise training. The regulation of myosins during early
myogenesis did not affect muscle histology 30 days after CTX
injection when muscle regeneration is completed (Fig. S2).
However, this does not exclude functional deficiencies. Indeed,
the miR-206 knockout mouse also showed a normal muscle
architecture at day 30 after CTX injection, but displayed
decreased muscle function during downhill running when miR-
206 was genetically deleted in the chronic regeneration model, mdx
(Liu et al., 2012). Future studies should address the consequences of
the genetic deletion of miR-501 on exercise capacity. Targeting
miR-501 could provide a unique opportunity to study the role of
myosin heavy chain regulation in muscle regeneration.
Isoform-1 of the Clcn5 gene encodes a Cl−/H+-exchanger highly
expressed in kidneys where it plays a crucial role in the process of
endocytosis in the proximal tubule (Piwon et al., 2000; Christensen
et al., 2003). Mutations that alter Clcn5 isoform-1 function can
cause Dent’s disease in humans, characterized by tubular
proteinuria, hypercalciuria, nephrolithiasis, nephrocalcinosis and
chronic renal failure (Devuyst and Thakker, 2010). The function of
isoform-2 has not been reported, but based on its specific
upregulation during muscle regeneration, this isoform deserves
further functional characterization during this process. Assuming
that isoform-2 is a functional chloride channel, it is possible that it
might play a role in the cell cycle and proliferation of the muscle
progenitors as hyperpolarization of stem cells has been reported to
inhibit proliferation (Blackiston et al., 2009; Li and Deng, 2011).
Our studies confirm that miR-501 is a muscle-specific miRNA
also based on its detection in skeletal muscle and serum from the
mdxmouse. Circulating miR-501 levels correlate with the activity of
skeletal muscle regeneration in mdx mice. MyomiRs have a great
potential to be used as biomarkers for muscle diseases because their
detection in serum is not confounded by contamination from blood
or endothelial cells. Indeed, miR-1, miR-133 and miR-206 have
been used to detect disease activity in muscle dystrophic animal
models and patients (Cacchiarelli et al., 2011; Mizuno et al., 2011;
Roberts et al., 2012, 2013). However, these inductions do not
always correlate with the respective levels of the myomiRs in
skeletal muscle itself as miR-1 and miR-133a were either decreased
or unchanged in mdx muscle tissue (Mizuno et al., 2011; Roberts
et al., 2012). In addition, miR-206 was shown to be already
upregulated in serum from 2-week-oldmdxmice, indicating that this
miRNA can reach the circulation in the absence of muscle damage
(Roberts et al., 2013). Moreover, miR-1 and miR-133a are also
expressed in heart tissue, and miR-206 is preferentially expressed in
type 1 muscle fibers (Liu et al., 2012). Hence, it is not clear whether
the elevation of these previously known myomiRs in serum reflects
muscle mass, muscle type, damage or regeneration. The specific
expression of miR-501 in activated MPs of the skeletal muscle
lineage presents a unique advantage for its use as a biomarker that
deserves further testing in patient samples. The use of miR-501 as a
biomarker in serummight also be extended to other clinical settings,
for example to monitor the response of skeletal muscle to exercise.
Because the number of activated MPs in skeletal muscle also
increases during exercise interventions (Kadi et al., 2004; Dreyer
et al., 2006; Petrella et al., 2008; Verney et al., 2008), non-invasive
testing for the activation of MPs using miR-501 in serum could
provide important information about the efficiency of different
exercise protocols in humans.
miRNA expression has been previously studied in adult muscle
stem cells using qRT-PCR-based miRNAmicroarrays (Cheung et al.,
2012) or computational predictions (Farina et al., 2012). In the
present study, we used RNA deep sequencing to identify novel
muscle-specific miRNAs. The close genomic localization of miR-
501 and miR-362 in mouse and human of <700 nucleotides and their
similar expression pattern in MP and FAP indicates that they are
transcribed as a miRNA cluster. MiRNAs that reside on polycistronic
transcripts are processed with different efficiencies despite being co-
transcribed (Chakraborty et al., 2012; Chaulk et al., 2014), which
could explain the higher abundance of miR-501 compared with miR-
362. We have recently described a similar phenomenon for the miR-
29a/b cluster in mouse and human muscle cells (Galimov et al.,
2016). We currently lack sufficient evidence to conclude that other
miRNAs located in the Clcn5-2 intron also share the miR-362/-501
cluster. The strong induction of miR-501 upon activation of MPs is
not observed for its host gene Clcn5 isoform-2. This disconnection
between the abundance of the host gene and the mature miRNA
levels is not clear, but is consistent with the complex regulation of
polycistronic miRNA transcripts (Chakraborty et al., 2012; Chaulk
et al., 2014). Although we cannot exclude the possibility that the
miR-362/-501 cluster has an independent promoter, the striking co-
expression of Clcn5-2 and miR-501 during muscle regeneration still
favors a shared promoter region for the two genes.
The effect size for the upregulation of gigaxonin mRNA after
miR-501 inhibition during muscle regeneration in vivo was small.
However, gigaxonin is ubiquitously expressed and might reach
much higher expression levels in neurons and nerve endings
compared with muscle, which might dilute the observed effects after
inhibition of miR-501. Because a single miRNA usually targets
many different genes, it is also likely that there are other targets of
miR-501 than gigaxonin yet to be discovered. Further studies that
employ sequencing studies in vivo should reveal additional targets
of miR-501 also involved in muscle regeneration and the formation
of myosin.
In conclusion, we found that the novel myomiR 501 is a critical
checkpoint during muscle regeneration to prevent the expression of
genes such as gigaxonin that are disadvantageous for the newly
formed myofiber. Unraveling this pathway might lead to new
pharmacological strategies to enhance muscle regeneration and
prevent muscle wasting in disease states such as cachexia or aging.
MATERIALS AND METHODS
Mice
C57BL6/6J or C57BL/10ScSn-Dmdmdx mice were purchased from Harlan
or Jackson Laboratories, respectively. Animals were housed in a pathogen-
free animal facility in University Hospital Zurich on an inverted 12-h light
cycle (dark phase began at 06.00 h), fed ad libitum with chow diet. All
animal studies were approved by the ethics committee of the Canton of
Zurich Veterinary Office. Guidelines set by the Swiss Federal Veterinary
Office were followed in all procedures.
Cardiotoxin and antagomir injection
Cardiotoxin from Naja mossambica mossambica (Sigma-Aldrich) was
dissolved in PBS to a final concentration of 10 µM and injected into
C57BL6/6J mouse TAmuscles at 50 µl per muscle. Antagomir (7.5 µg) was
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injected at the indicated time points (50 µl per muscle). Antagomirs were
ordered in full-length complementarity to miR-501 with the previously
described modifications (Krützfeldt et al., 2005) from Sigma-Aldrich. For
tissue harvesting, TA muscles were dissected, snap-frozen in liquid nitrogen
and stored at −80°C.
Measurement of creatine kinase activity and serum collection
Mice were euthanized by CO2 inhalation, blood was collected using 25G
syringes from heart ventricles and transferred to 1.5 ml eppendorf tubes to
coagulate. Tubes were centrifuged at 2000 g for 8 min and the supernatant
was again centrifuged at 12,000 g for 15 min to precipitate the residual cell
debris. Serum creatine kinase activity was measured using a Creatine Kinase
Activity Assay Kit (Sigma-Aldrich) according to the manufacturer’s
instructions.
Isolation of primary myogenic and fibro/adipogenic progenitors
Mouse TA muscles were minced in cold PBS on ice and digested with
collagenase type II (Life Technologies). Resulting cells were suspended in 0.5%
bovine serum albumin in PBS and incubated with the respective antibodies on a
rotating chamber at 4°C. 7-AAD (7-aminoactinomycin D; A9400, Sigma-
Aldrich) was used to exclude dead cells. The following antibodies were used:
Alexa Fluor 488 anti-mouse CD45 (clone 30-F11, Biolegend), Alexa Fluor 488
anti-mouse CD31 (clone 390, Biolegend), APC anti-mouse SCA1 (clone D7,
Biolegend) and PE anti-mouse alpha7-integrin (FAB3518P, R&D Systems).
Sorting was performed on a FACSAria III (BD Biosciences).
Analysis of proliferation of muscle-resident progenitors
Twelve hours before harvesting the muscle tissue, mice were injected with
10 µg/g bodyweight EdU intraperitoneally. After collagenase digestion,
cells were subjected to staining for detection of the incorporated EdU using
the Click-iT EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life
Technologies) according to the manufacturer’s instructions.
Culture and transfection of primarymyoblasts and HEK293 cells
Cells were cultured on collagen-coated plates in growth media, consisting of
40% (v/v) low-glucose DMEM, 40% (v/v) HAM’s F-10 medium, 20% fetal
bovine serum, 5 ng/ml basic fibroblast growth factor, and 100 U/ml
Penicillin/Streptomycin (all from Life Technologies). To induce
differentiation, myoblasts were transferred to differentiation media (low-
glucose DMEM supplemented with 2% horse serum and 100 U/ml
Penicillin/Streptomycin) after reaching 80% confluency. Lipofectamine
RNAiMax was used for transfecting miRNA mimics (MISSION miRNA,
Sigma-Aldrich) or antagomirs to the cells. Final concentration was 38 nM
for mimics and 12 nM for antagomirs, respectively. Lipofectamine LTXwas
used for DNA transfection, and co-transfection of DNA with miRNA
mimics or antagomirs was performed using Lipofectamine 2000. All
reagents were purchased from Invitrogen, and transfection was performed
according to the manufacturer’s instructions. MG-132 (474790) was
obtained from Merck Millipore. HEK 293 cells were cultured in high-
glucose DMEM supplemented with 10% fetal bovine serum and 100 U/ml
Penicillin/Streptomycin (all from Life Technologies). Lipofectamine 2000
(Invitrogen) was used for co-transfection of DNA with miRNA mimics or
antagomirs, according to the manufacturer’s instructions.
RNA isolation and qRT-PCR
Total RNA was isolated using Trizol reagent (Invitrogen) according to the
manufacturer’s instructions. RNAClean-Up and Concentration Kit (Norgen
Biotek) was used for RNA extraction from sorted myogenic progenitors.
Isolation of RNA from serum was performed using miRNeasy Mini Kit
(Qiagen) from 50 µl serum added to 700 µl Qiazol (Qiagen) and spiked with
cel-miR-39 as an internal control, according to the manufacturer’s
instructions. After using the RNase-free DNase I Kit (Ambion), RNA was
precipitated in 70% ethanol containing 0.1 M ammonium acetate at −80°C
overnight. First-strand cDNAwas synthesized using SuperScript III Reverse
Transcriptase Kit (Thermo Fisher Scientific) with random hexamers
according to the manufacturer’s instructions. FastStart Universal SYBR
GreenMaster (Roche) was used to run the real-time PCR reactions on a 7500
Fast Real-Time PCR system (Applied Biosystems). Primer sequences are
listed in Table S1. Three primer sets were designed for measuring Clcn5
gene expression: a general primer set (FC and RC), which amplifies both
Clcn5 splice variants, a primer set specific for isoform 1 (F1 and R1,2), and a
primer set specific for isoform 2 (F2 and R1,2) as indicated in Fig. 3A. First,
two PCR reactions were performed on a mouse cDNA sample with either F1
and RC, or F2 and RC primers. PCR products were purified and named Iso1-
std and Iso2-std, respectively. As the binding site for RC primer is
downstream of that of R1,2, each of the resulting PCR products contained the
part that could be amplified by the general primers (FC and RC) preceded by
their corresponding isoform-specific sequence. Serial dilutions of Iso1-std
and Iso2-std were used as standard samples to quantify isoform-1 or
isoform-2 transcripts, respectively, using the isoform-specific primers. In a
separate reaction, using FC and RC primers, the Iso1-std serial dilutions were
measured against serial dilutions of Iso2-std as standards. This enabled
adjustment of the absolute copy numbers ascribed to the Iso1-std serial
dilutions, and consequently scaling of the values obtained for isoform 1 to
those for isoform 2. For quantification of miRNA levels, first-strand cDNA
synthesis and qPCR reactions were performed using TaqMan MicroRNA
Reverse Transcription Kit (Applied Biosystems) and TaqMan Universal
PCR Master Mix (Thermo Fisher Scientific), respectively.
RNA sequencing
RNA sequencing was carried out as a service by LC Sciences (Houston, TX,
USA). Expression of miRNAs were measured by the relative frequency of
reads assigned to each miRNA and stated as RPM (reads per million). For
mRNA sequencing, miRNeasy Mini Kit (Qiagen) was used, accompanied by
on-column DNase-treatment according to the manufacturer’s instructions.
Poly (A) enrichment, library preparation and single-end sequencing of 100-
nucleotide sequences on Illumina HiSeq-2000 was performed as a service by
the Functional Genomics Center Zurich (FGCZ). Mapping of raw sequence
reads to the genome was performed using bowtie program with mouse
genome build mm10 as reference. Transcript quantification and differential
expression analysis were performed using RSEM and edgeR software,
respectively, on Bioconductor package in R. FastQC program in Java was
used for quality control of the high-throughput data.
Northern blotting
Polyacrylamide gels were used to separate 15 µg of total RNA. RNA bands
were visualized by incubating the gels after electrophoresis in 0.5 µg/ml
ethidium bromide and RNA was transferred onto Hybond+ membranes
(Amersham). The membrane was dried and cross-linked under UV radiation
(1200 J/m2) and hybridized with a radioactively labeled probe (γ-32P-ATP,
10 mCi/ml). The washed membrane was exposed to a phosphorimager to
detect the radioactivity signal. Signal density of the bands was measured
using ImageJ (NIH).
Western blotting
Cells were lysed in RIPA buffer (25 mM Tris HCl pH 7.6, 150 mM NaCl,
1% NP-40, 1% sodium deoxycholate, 0.1% SDS) supplemented with
complete EDTA-free protease inhibitor cocktail and PhosSTOP phosphatase
inhibitor cocktail (Roche). SDS-PAGE was performed on NuPAGE Novex
4-12% Bis-Tris protein gels, and separated with SDS running buffer at
120 V. The gel was then used for Coomassie Blue staining or western
blotting to PDVF membrane using Mini Trans-Blot Cell chambers (Bio-
Rad). Membranes were incubated at 4°C with the primary antibodies for at
least 16 h [anti-total myosin heavy chain from DSHB, MF-20 (1:100), anti-
myosin heavy chain-3 from Santa Cruz (sc-53091; 1:500), anti-desmin from
Sigma (D1033; 1:200), anti-GAPDH from ProteinTech (10494-1-AP;
1:1000), anti-gigaxonin from Proteintech (14305-1-AP; 1:500)]. Incubation
with appropriate HRP-conjugated secondary antibodies and the Lumi-Light
western blotting substrate (Roche) was used to detect the signal in a LAS-
3000 imager (Fujifilm). Densitometry analysis of the images was carried out
using Aida image analyzer software v.2.3.
Luciferase activity assay
The 3′UTR fragments of the selected genes were amplified by PCR from
human muscle cDNA using high fidelity PCR enzyme mix (Thermo
Scientific). PCR products were cloned in pCR2.1 vector using TOPO TA
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cloning kit (Life Technologies) and subcloned into pmirGLO Dual-
Luciferase miRNATarget Expression Vector (Promega), downstream of the
firefly luciferase open reading frame (ORF). Mutagenesis of the miR-501
seedmotif in the 3′UTRofGanwas performed using the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies). To make the miR-501
sensor construct, two pairs of oligonucleotides each pair harboring a full
complementary biding site for miR-501, were annealed and cloned into the
XbaI site after firefly luciferase ORF in pmirGLO vector. DNA constructs
were transfected to HEK 293 cells or primary myoblasts along with miRNA
mimics or antagomirs using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Final concentrations of DNA, miRNA mimic
and antagomirs were 200 ng/ml, 38 nM and 12 nM, respectively. Activity of
Firefly and Renilla luciferase enzymes was measured using Dual-Luciferase
Reporter Assay System (Promega) with a Tecan plate reader.
Generation of overexpression DNA constructs
A double-stranded DNA molecule containing the Kozak consensus
sequence including start codon (ATG) followed by a sequence encoding
the FLAG-tag (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) was made by
annealing two oligonucleotides and ligated into pcDNA3.1 (+)
mammalian expression vector (Invitrogen). The resulting construct
(pcDNA-Kozak-Flag) was used to make overexpression constructs
encoding for FLAG-tagged proteins. ORFs of the respective genes were
amplified by PCR from mouse multi-tissue cDNA using high fidelity PCR
enzyme mix (Thermo Scientific) and specific primers. Primer sequences are
listed in Table S1. A HindIII restriction site was included at the end of both
forward and reverse primers. PCR products were digested with HindIII
enzyme and cloned in theHindIII site of the pcDNA-Kozak-Flag vector. All
constructs were confirmed by restriction mapping and DNA sequencing.
Skeletal muscle immunofluorescence
Skeletal muscle was dissected and flash frozen in isopentane/liquid
nitrogen. Frozen sections of 10 µm were prepared from three different
areas of the tibialis anterior muscle, 500 µm apart. Sections were then
processed for immunofluorescence using the Vector M.O.M.
Immunodetection Kit and protocol (Vector Laboratories). Slides were
mounted with Fluoroshield with DAPI (Sigma). Antibodies against eMHC
(BF-G6, 1:20) were obtained from the Developmental Studies Hybridoma
Bank, University of Iowa and antibodies against laminin (L9393, 1:500)
were obtained from Sigma. Images for each section were obtained using
Leica confocal laser scanning microscope SP5 Mid UV-VIS and evaluated
for fiber and cell counts using Ilastic and ImageJ software.
Statistical analysis
Unless specified otherwise, two-sided unpaired Student’s t-test was used to
compare sample groups, and the null hypothesis (no difference between the
groups) was rejected if P<0.05. When applicable, one-sample t-test with a
hypothetical mean value of 1 was used to analyze the significance based on
fold-change values. Differential expression analysis of RNA-seq data was
performed by edgeR software. Data in bar graphs are shown as mean±s.e.m.
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